公开(公告)号：US10927109B2

公开(公告)日：2021-02-23

申请号：US16333079

申请日：2017-09-06

申请人： Bayer Aktiengesellschaft ,  Bayer Pharma Aktiengesellschaft

发明人： Henrik Teller ,  Alexandros Vakalopoulos ,  Melissa Boultadakis Arapinis ,  Alexander Straub ,  Hanna Tinel ,  Markus Brechmann ,  Matthias Beat Wittwer ,  Maximilian Andreas Kullmann ,  Till Freudenberger ,  Thomas Mondritzki ,  Tobias Marquardt

IPC分类号： C07D471/04 ,  A61K31/4375 ,  A61P9/06 ,  A61K31/551 ,  A61K45/06 ,  C07D491/107 ,  C07D519/00 ,  A61P9/00 ,  A61P13/00

摘要： The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

公开(公告)号：US10519154B2

公开(公告)日：2019-12-31

申请号：US16317322

申请日：2017-07-04

申请人： Bayer Pharma Aktiengesellschaft ,  Bayer Aktiengesellschaft

发明人： Henrik Teller ,  Melissa Boultadakis Arapinis ,  Alexandros Vakalopoulos ,  Anne-Sophie Rebstock ,  Alexander Straub ,  Hanna Tinel ,  Markus Brechmann ,  Matthias Beat Wittwer ,  Maximillian Andreas Kullmann ,  Klaus Münter ,  Thomas Mondritzki ,  Tobias Marquardt

IPC分类号： C07D471/04 ,  A61P9/06 ,  A61P13/12 ,  A61P9/04

摘要： The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

公开(公告)号：US11472803B2

公开(公告)日：2022-10-18

申请号：US17161201

申请日：2021-01-28

申请人： Bayer Aktiengesellschaft ,  Bayer Pharma Aktiengesellschaft

发明人： Henrik Teller ,  Alexandros Vakalopoulos ,  Melissa Boultadakis Arapinis ,  Alexander Straub ,  Hanna Tinel ,  Markus Brechmann ,  Matthias Beat Wittwer ,  Maximillian Andreas Kullmann ,  Till Freudenberger ,  Thomas Mondritzki ,  Tobias Marquardt

IPC分类号： C07D471/04 ,  A61P9/06 ,  A61K31/4375 ,  A61K31/551 ,  A61K45/06 ,  C07D491/107 ,  C07D519/00 ,  A61P9/00 ,  A61P13/00

摘要： The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

公开(公告)号：US10435403B2

公开(公告)日：2019-10-08

申请号：US15735138

申请日：2016-06-06

申请人： Bayer Pharma Aktiengesellschaft

发明人： Henrik Teller ,  Alexander Straub ,  Markus Brechmann ,  Thomas Müller ,  Mark Meininghaus ,  Katrin Nowak-Reppel ,  Hanna Tinel ,  Klaus Münter ,  Daniela Fliegner ,  Thomas Mondritzki ,  Melissa Boultadakis Arapinis ,  Tobias Marquardt ,  Alexandros Vakalopoulos ,  Anne-Sophie Rebstock ,  Matthias Beat Wittwer

IPC分类号： C07D471/04 ,  A61P9/04 ,  A61K31/4375 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5377 ,  A61K45/06 ,  C07D519/00

摘要： The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.